Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments
Expert Review of Clinical Pharmacology · 2023
DOI: 10.1080/17512433.2023.2174524 ↗Kurz gefasst
Editorial in der Zeitschrift Expert Review of Clinical Pharmacology, 2023. Verfasst von Georgios Polychronopoulos und 2 weiteren Autor:innen. Beteiligte Einrichtung: First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Lipoprotein(a), Cardiovascular Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Lipoprotein (a) appears to play a causal role in the pathogenesis of cardiovascular disease (CVD) [1,2]. In a meta-analysis of 36 prospective studies in subjects without established CVD (n = 126,634), Lp(a) levels showed a continuous and independent association with coronary heart disease (CHD) and ischemic stroke during 1.3 million person-years of follow-up [3]. In a meta-analysis of 7 statin outcome trials (n = 29,069; 52% with established CVD), both baseline and on-statin Lp(a) levels showed a linear and independent association with cardiovascular events [4]. Genetic variants associated with increased levels of Lp(a) are also independently related to increased incidence of CHD [5,6]. Currently, no agents that specifically lower Lp(a) levels are commercially available [1,2]. Statins have no effect or might slightly increase Lp(a) levels [4]. Niacin lowers Lp(a) levels modestly (by approximately 20–25%) but had no effect on cardiovascular events in two large, randomized, controlled trials [7,8]. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors also lower Lp(a) levels by approximately 25% and this reduction was shown to contribute independently to the reduction in cardiovascular morbidity [9]. Mipomersen, an antisense oligonucleotide targeting apoB, lowers Lp(a) levels by 21–31% but is approved only by the FDA and only in patients with homozygous familial hypercholesterolemia [10]. Lp(a) apheresis substantially lowers Lp(a) levels (by > 60%) and is recommended in some European countries in patients with early-onset or progressive CVD [11]. Hormone replacement therapy also reduces Lp(a) levels by 25% in postmenopausal women [12]. Finally, several nutraceuticals, including flaxseed oil, phytosterols, l-carnitine and coenzyme Q10 were shown to lower Lp(a) levels [13–15]. Recently, several agents that specifically lower Lp(a) have been developed. In an early randomized, double-blind, placebo-controlled trial in healthy volunteers with Lp(a) levels ≥ 75 nmol/l, pelacarsen (formerly known as IONISAPO(a)-LRx, AKCEA-APO(a)-LRx and TQJ230), an antisense oligonucleotide targeting apolipoprotein(a) that is conjugated with a triantennary N-acetylgalactosamine (GalNAc3) moiety, a high-affinity ligand for the asialoglycoprotein receptor on the surface of hepatocytes, which increases its affinity to hepatocytes, administered as a single dose of 10–120 mg or as multiple doses of 10 mg, 20 mg, or 40 mg at day 1, 3, 5, 8, 15, and 22, reduced Lp(a) levels by 66–92% [16]. No adverse events were reported [10]. In a more recent randomized, double-blind, placebo-controlled, dose-ranging trial in 286 patients with established CVD and screening LP(a) levels ≥ 60 mg/dl (150 nmol/l), pelacarsen at a dose of 20, 40, or 60 mg every 4 weeks, 20 mg every 2 weeks, or 20 mg every week, induced dose-dependent reductions in Lp(a) levels (from 35 to 80%) at 6 months [17]. Notably, the 60 mg every 4 weeks regimen yielded the largest reduction in Lp(a) levels, which was comparable with the 20 mg every week regimen (72 and 80%, respectively) [17]. The reduction in Lp(a) levels appears to be independent of baseline Lp(a) levels, gene variants and isoform size [18]. The commonest adverse effect of pelacarsen was injection-site reaction whereas the rates of adverse effects on platelet count, liver and renal function did not differ from the placebo group [17]. The ongoing double-blind, placebo-controlled, randomized Lp(a)HORIZON trial (NCT04023552) is evaluating the effects of pelacarsen 80 mg every 4 weeks on cardiovascular events in 8,324 patients with Lp(a) levels ≥ 70 mg/ dl and established CVD (history of myocardial infarction or ischemic stroke, or symptomatic peripheral arterial disease) [19]. The estimated study completion date is in May of 2025 [19]. Olpasiran (formerly AMG890) is a N-acetylgalactosamineconjugated, small interfering RNA that inhibits apolipoprotein(a) messenger RNA translation in hepatocytes [20,21]. In phase 1 studies, a single 3, 9, 75, or 225 mg dose of olparisan reduced Lp(a) levels by 56–99% and was well-tolerated [20,21]. The effects of olpasiran on major CHD events (myocardial infarction, urgent coronary revascularization or death due to CHD) will be evaluated in the The Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) – Outcomes Trial, a randomized, double-blind, placebo-controlled study, that will enroll 6,000 patients with Lp(a) levels ≥ 200 nmol/l and established CHD (history of myocardial infarction or history of percutaneous coronary intervention with stenting and at least 1 additional risk factor) [22]. The estimated study completion date is in December of 2026 [22].
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.
Zitieren
APA
Polychronopoulos, G., Papagiannis, A., & Tziomalos, K. (2023). Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2023.2174524
Vancouver
Polychronopoulos G, Papagiannis A, Tziomalos K. Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments. Expert Review of Clinical Pharmacology. 2023. doi:10.1080/17512433.2023.2174524
BibTeX
@article{Polychronopoulos2023,
author = {Polychronopoulos, Georgios and Papagiannis, Achilleas and Tziomalos, Konstantinos},
title = {Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments},
journal = {Expert Review of Clinical Pharmacology},
year = {2023},
doi = {10.1080/17512433.2023.2174524}
}
EUVIMED